378 related articles for article (PubMed ID: 23696296)
21. A New Ophthalmic Pharmaceutical Formulation, Topical Sulglycotide, Enhances the Ocular Mucin Secretion in Desiccation Stress-Mediated Dry Eye Disease.
Lee H; Jeon S; Kim CE; Park YJ; Yang J
Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):1076-1087. PubMed ID: 30901389
[TBL] [Abstract][Full Text] [Related]
22. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
[TBL] [Abstract][Full Text] [Related]
23. The Efficacy of 2% Topical Rebamipide on Conjunctival Squamous Metaplasia and Goblet Cell Density in Dry Eye Disease.
Simsek C; Dogru M; Shinzawa M; Den S; Kojima T; Iseda H; Suzuki M; Shibasaki Y; Yoshida N; Shimazaki J
J Ocul Pharmacol Ther; 2019; 35(6):350-358. PubMed ID: 31259647
[No Abstract] [Full Text] [Related]
24. Effects of DA-6034 on aqueous tear fluid secretion and conjunctival goblet cell proliferation.
Choi SM; Lee YG; Seo MJ; Kang KK; Ahn BO; Yoo M
J Ocul Pharmacol Ther; 2009 Jun; 25(3):209-14. PubMed ID: 19456255
[TBL] [Abstract][Full Text] [Related]
25. Secreted Mucins on the Ocular Surface.
Hori Y
Invest Ophthalmol Vis Sci; 2018 Nov; 59(14):DES151-DES156. PubMed ID: 30481820
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effects of topical doxycycline in a benzalkonium chloride-induced mouse dry eye model.
Zhang Z; Yang WZ; Zhu ZZ; Hu QQ; Chen YF; He H; Chen YX; Liu ZG
Invest Ophthalmol Vis Sci; 2014 May; 55(5):2963-74. PubMed ID: 24722696
[TBL] [Abstract][Full Text] [Related]
27. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
28. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye.
Sawazaki R; Ishihara T; Usui S; Hayashi E; Tahara K; Hoshino T; Higuchi A; Nakamura S; Tsubota K; Mizushima T
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2547-56. PubMed ID: 24677100
[TBL] [Abstract][Full Text] [Related]
29. Significance of mucin on the ocular surface.
Watanabe H
Cornea; 2002 Mar; 21(2 Suppl 1):S17-22. PubMed ID: 11995804
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome.
Žiniauskaite A; Ragauskas S; Hakkarainen JJ; Rich CC; Baumgartner R; Kalesnykas G; Albers DS; Kaja S
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3088-3093. PubMed ID: 30025146
[TBL] [Abstract][Full Text] [Related]
31. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Kim CE; Kleinman HK; Sosne G; Ousler GW; Kim K; Kang S; Yang J
Sci Rep; 2018 Jul; 8(1):10500. PubMed ID: 30002412
[TBL] [Abstract][Full Text] [Related]
32. A murine model of dry eye induced by an intelligently controlled environmental system.
Chen W; Zhang X; Zhang J; Chen J; Wang S; Wang Q; Qu J
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1386-91. PubMed ID: 18385054
[TBL] [Abstract][Full Text] [Related]
33. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease.
Solomon A; Dursun D; Liu Z; Xie Y; Macri A; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2283-92. PubMed ID: 11527941
[TBL] [Abstract][Full Text] [Related]
34. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma.
De Paiva CS; Villarreal AL; Corrales RM; Rahman HT; Chang VY; Farley WJ; Stern ME; Niederkorn JY; Li DQ; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2553-60. PubMed ID: 17525184
[TBL] [Abstract][Full Text] [Related]
35. [Emphasizing the prevention and anti-inflammation research of dry eye disease].
Zhang MC; Bian F
Zhonghua Yan Ke Za Zhi; 2013 Jan; 49(1):6-7. PubMed ID: 23601457
[TBL] [Abstract][Full Text] [Related]
36. In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression.
Lambiase A; Micera A; Pellegrini G; Merlo D; Rama P; De Luca M; Bonini S; Bonini S
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4622-30. PubMed ID: 19407015
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targets in dry eye syndrome.
Peral A; Domínguez-Godínez CO; Carracedo G; Pintor J
Drug News Perspect; 2008 Apr; 21(3):166-76. PubMed ID: 18560615
[TBL] [Abstract][Full Text] [Related]
38. Ocular mucins in dry eye disease.
Portal C; Gouyer V; Gottrand F; Desseyn JL
Exp Eye Res; 2019 Sep; 186():107724. PubMed ID: 31325452
[TBL] [Abstract][Full Text] [Related]
39. Time course of ocular surface and lacrimal gland changes in a new scopolamine-induced dry eye model.
Viau S; Maire MA; Pasquis B; Grégoire S; Fourgeux C; Acar N; Bretillon L; Creuzot-Garcher CP; Joffre C
Graefes Arch Clin Exp Ophthalmol; 2008 Jun; 246(6):857-67. PubMed ID: 18357464
[TBL] [Abstract][Full Text] [Related]
40. Antiinflammatory therapy for dry eye.
Pflugfelder SC
Am J Ophthalmol; 2004 Feb; 137(2):337-42. PubMed ID: 14962426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
